Welcome to our dedicated page for Dynatronics news (Ticker: DYNT), a resource for investors and traders seeking the latest updates and insights on Dynatronics stock.
Dynatronics Corporation (DYNT) is a medical device company that has focused on restorative products for physical therapy, rehabilitation, orthopedics, pain management, and athletic training. Company news has highlighted its role as a manufacturer serving clinical and athletic training environments, with products marketed under brands such as Bird & Cronin®, Solaris™, Hausmann®, Physician's Choice®, and PROTEAM™.
News releases for Dynatronics have covered several recurring themes. Earnings announcements and quarterly financial results provide updates on net sales, gross profit margins, operating performance, and guidance for future fiscal periods. Management commentary in these releases has discussed sales goals, operating plans, and strategic priorities, including product development and business optimization efforts.
Dynatronics’ news flow has also included product and portfolio updates, such as references to new additions to its rehabilitation furniture line, which the company associates with treatment furniture and athletic training center products. Corporate governance and leadership changes have been another focus, with announcements about board appointments and executive hires, including changes in the chief financial officer role and additions to the Board of Directors.
Trading and listing developments have been an important part of Dynatronics’ public communications. In June 2024, the company announced that it had received notice from The Nasdaq Stock Market regarding suspension of trading due to minimum bid price noncompliance and that it would transition its common stock quotation to the OTCQB Venture Market. Later, in January 2026, an 8-K reported that Dynatronics and its subsidiaries ceased operations and filed for Chapter 7 bankruptcy, marking a significant change in the company’s status.
Investors and researchers using this news page can review historical press releases and related coverage to understand Dynatronics’ business focus, financial performance, leadership changes, trading venue transition, and its subsequent Chapter 7 bankruptcy filing.
Dynatronics Corporation (NASDAQ:DYNT) reported its Q2 fiscal year 2023 results, showcasing total net sales of $10.9 million and a gross profit margin increase to 28.1% from 19.8% a year prior. Net loss improved to $0.8 million, down from $1.4 million, and current liabilities reduced by $1.0 million. The company reaffirmed its net sales guidance for fiscal year '23 at $45 million to $48 million, projecting a 5% improvement from the previous year. However, it deferred gross margin guidance due to inflationary pressures and other economic challenges.
Dynatronics Corporation (NASDAQ:DYNT) announced a 1-for-5 reverse stock split effective February 1, 2023, at 5:00 p.m. (ET) to comply with NASDAQ's minimum bid price requirement. As a result, outstanding shares will reduce from approximately 19.6 million to 3.9 million. The common stock will trade on a split-adjusted basis starting February 2, 2023. The reverse stock split will not affect the Series A and B preferred stock, though their conversion ratios will change. The company seeks to maintain compliance with NASDAQ's listing requirements, but no guarantees can be made regarding future compliance.
Dynatronics Corporation (NASDAQ:DYNT) announced its second-quarter financial results for fiscal year 2023, scheduled for release on February 9, 2023, before market open. Following the results, a conference call will take place at 8:00 AM ET, featuring management remarks, a slide presentation, and a Q&A session. Interested participants can access the call by dialing specific numbers provided in the release, and a replay will be available until February 16, 2023. The company manufactures products for athletic training, physical therapy, and rehabilitation, emphasizing its commitment to high-quality restorative solutions.
Dynatronics Corporation (NASDAQ:DYNT) reported its Q1 fiscal year 2023 results, revealing net sales of $12.1 million and a gross profit margin increase to 30.2% from 23.4% in Q4 FY22. The net loss improved to $0.5 million from $1.6 million. The company maintains a debt-free status for the 9th consecutive quarter. Guidance for FY23 net sales is set at $45 million to $48 million, a 5% increase from FY22. However, due to inflation, gross margin guidance is deferred as the company anticipates continued volatility from economic challenges.